Abeer M Shaaban1, Bridget Hilton2, Karen Clements2, Elena Provenzano3,4, Shan Cheung2, Matthew G Wallis3,4, Elinor Sawyer5, Jeremy S Thomas6, Andrew M Hanby7, Sarah E Pinder5, Alastair M Thompson8. 1. Queen Elizabeth Hospital Birmingham and University of Birmingham, Birmingham, UK. a.shaaban@bham.ac.uk. 2. Screening Quality Assurance Service, Public Health England, Birmingham, UK. 3. Addenbrookes Hospital, Cambridge, UK. 4. Cambridge Breast Unit, and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Trust, Cambridge, UK. 5. School of Cancer & Pharmaceutical Sciences, King's College London and Guy's and St Thomas' Hospitals NHS Foundation Trust, London, UK. 6. Western General Hospital, Edinburgh, UK. 7. Leeds Institute of Medical Research at St. James's, St James's University Hospital, Leeds, UK. 8. Baylor College of Medicine, Houston, TX, USA.
Abstract
BACKGROUND: The Sloane audit compares screen-detected ductal carcinoma in situ (DCIS) pathology with subsequent management and outcomes. METHODS: This was a national, prospective cohort study of DCIS diagnosed during 2003-2012. RESULTS: Among 11,337 patients, 7204 (64%) had high-grade DCIS. Over time, the proportion of high-grade disease increased (from 60 to 65%), low-grade DCIS decreased (from 10 to 6%) and mean size increased (from 21.4 to 24.1 mm). Mastectomy was more common for high-grade (36%) than for low-grade DCIS (15%). Few (6%) patients treated with breast-conserving surgery (BCS) had a surgical margin <1 mm. Of the 9191 women diagnosed in England (median follow-up 9.4 years), 7% developed DCIS or invasive malignancy in the ipsilateral and 5% in the contralateral breast. The commonest ipsilateral event was invasive carcinoma (n = 413), median time 62 months, followed by DCIS (n = 225), at median 37 months. Radiotherapy (RT) was most protective against recurrence for high-grade DCIS (3.2% for high-grade DCIS with RT compared to 6.9% without, compared with 2.3 and 3.0%, respectively, for low/intermediate-grade DCIS). Ipsilateral DCIS events lessened after 5 years, while the risk of ipsilateral invasive cancer remained consistent to beyond 10 years. CONCLUSION: DCIS pathology informs patient management and highlights the need for prolonged follow-up of screen-detected DCIS.
BACKGROUND: The Sloane audit compares screen-detected ductal carcinoma in situ (DCIS) pathology with subsequent management and outcomes. METHODS: This was a national, prospective cohort study of DCIS diagnosed during 2003-2012. RESULTS: Among 11,337 patients, 7204 (64%) had high-grade DCIS. Over time, the proportion of high-grade disease increased (from 60 to 65%), low-grade DCIS decreased (from 10 to 6%) and mean size increased (from 21.4 to 24.1 mm). Mastectomy was more common for high-grade (36%) than for low-grade DCIS (15%). Few (6%) patients treated with breast-conserving surgery (BCS) had a surgical margin <1 mm. Of the 9191 women diagnosed in England (median follow-up 9.4 years), 7% developed DCIS or invasive malignancy in the ipsilateral and 5% in the contralateral breast. The commonest ipsilateral event was invasive carcinoma (n = 413), median time 62 months, followed by DCIS (n = 225), at median 37 months. Radiotherapy (RT) was most protective against recurrence for high-grade DCIS (3.2% for high-grade DCIS with RT compared to 6.9% without, compared with 2.3 and 3.0%, respectively, for low/intermediate-grade DCIS). Ipsilateral DCIS events lessened after 5 years, while the risk of ipsilateral invasive cancer remained consistent to beyond 10 years. CONCLUSION: DCIS pathology informs patient management and highlights the need for prolonged follow-up of screen-detected DCIS.
Authors: Abeer M Shaaban; Bridget Hilton; Karen Clements; David Dodwell; Nisha Sharma; Cliona Kirwan; Elinor Sawyer; Anthony Maxwell; Matthew Wallis; Hilary Stobart; Senthurun Mylvaganam; Janet Litherland; Samantha Brace-McDonnell; Joanne Dulson-Cox; Olive Kearins; Elena Provenzano; Ian O Ellis; Sarah E Pinder; Alastair M Thompson Journal: Br J Cancer Date: 2022-10-12 Impact factor: 9.075
Authors: Anna K Casasent; Mathilde M Almekinders; Charlotta Mulder; Proteeti Bhattacharjee; Deborah Collyar; Alastair M Thompson; Jos Jonkers; Esther H Lips; Jacco van Rheenen; E Shelley Hwang; Serena Nik-Zainal; Nicholas E Navin; Jelle Wesseling Journal: Nat Rev Cancer Date: 2022-10-19 Impact factor: 69.800
Authors: Abeer M Shaaban; Bridget Hilton; Karen Clements; Sarah E Pinder; Alastair M Thompson Journal: Br J Cancer Date: 2021-02-16 Impact factor: 7.640
Authors: Ki-Tae Hwang; Young Jin Suh; Chan-Heun Park; Young Joo Lee; Jee Ye Kim; Jin Hyang Jung; Seeyeong Kim; Junwon Min Journal: Oncologist Date: 2021-09-02
Authors: Jelle Wesseling; Michael Schaapveld; Maartje van Seijen; Esther H Lips; Liping Fu; Daniele Giardiello; Frederieke van Duijnhoven; Linda de Munck; Lotte E Elshof; Alastair Thompson; Elinor Sawyer; Marc D Ryser; E Shelley Hwang; Marjanka K Schmidt; Paula H M Elkhuizen Journal: Br J Cancer Date: 2021-08-18 Impact factor: 7.640
Authors: Matthew G Davey; Colm O'Flaherty; Eoin F Cleere; Aoife Nohilly; James Phelan; Evan Ronane; Aoife J Lowery; Michael J Kerin Journal: BJS Open Date: 2022-03-08